282 related articles for article (PubMed ID: 24418060)
1. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
2. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N; Yanai K
IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
[TBL] [Abstract][Full Text] [Related]
3. Brain amyloid imaging--FDA approval of florbetapir F18 injection.
Yang L; Rieves D; Ganley C
N Engl J Med; 2012 Sep; 367(10):885-7. PubMed ID: 22931256
[No Abstract] [Full Text] [Related]
4. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
Siderowf A; Pontecorvo MJ; Shill HA; Mintun MA; Arora A; Joshi AD; Lu M; Adler CH; Galasko D; Liebsack C; Skovronsky DM; Sabbagh MN
BMC Neurol; 2014 Apr; 14():79. PubMed ID: 24716655
[TBL] [Abstract][Full Text] [Related]
5. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
6. Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid.
Beach TG; Schneider JA; Sue LI; Serrano G; Dugger BN; Monsell SE; Kukull W
J Neuropathol Exp Neurol; 2014 Oct; 73(10):948-53. PubMed ID: 25192053
[TBL] [Abstract][Full Text] [Related]
7. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
de Lartigue J
Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
[TBL] [Abstract][Full Text] [Related]
8. Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.
Technol Eval Cent Assess Program Exec Summ; 2013 Feb; 27(5):1-4. PubMed ID: 23589929
[No Abstract] [Full Text] [Related]
9. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
10. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies.
Gupta HV; Beach TG; Mehta SH; Shill HA; Driver-Dunckley E; Sabbagh MN; Belden CM; Liebsack C; Dugger BN; Serrano GE; Sue LI; Siderowf A; Pontecorvo MJ; Mintun MA; Joshi AD; Adler CH
J Alzheimers Dis; 2021; 80(4):1603-1612. PubMed ID: 33720879
[TBL] [Abstract][Full Text] [Related]
12. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
[TBL] [Abstract][Full Text] [Related]
13. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
14. Current status of PET-imaging probes of β-amyloid plaques.
Koo J; Byun Y
Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
[TBL] [Abstract][Full Text] [Related]
15. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
[TBL] [Abstract][Full Text] [Related]
16. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
17. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
[TBL] [Abstract][Full Text] [Related]
18. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
19. Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making.
Zannas AS; Doraiswamy PM; Shpanskaya KS; Murphy KR; Petrella JR; Burke JR; Wong TZ
Neurocase; 2014 Aug; 20(4):466-73. PubMed ID: 23672654
[TBL] [Abstract][Full Text] [Related]
20. Use of florbetapir-PET for imaging beta-amyloid pathology.
Clark CM; Schneider JA; Bedell BJ; Beach TG; Bilker WB; Mintun MA; Pontecorvo MJ; Hefti F; Carpenter AP; Flitter ML; Krautkramer MJ; Kung HF; Coleman RE; Doraiswamy PM; Fleisher AS; Sabbagh MN; Sadowsky CH; Reiman EP; Zehntner SP; Skovronsky DM;
JAMA; 2011 Jan; 305(3):275-83. PubMed ID: 21245183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]